Merus

Merus NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors. The company was founded by Ton Logtenberg and Hennie Hoogenboom on June 16, 2003 and is headquartered in Utrecht, the Netherlands.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Shares have risen by 40% since my 2020 ROTY update, but have lost a third of their value in 2022. I provide a recap of our thesis on this promising platform technology play in the oncology space.

Merus: Precision Oncology Pioneer Continues To Execute In The Clinic

UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 05, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced interim efficacy data as of an April 12, 2022 data cutoff date, from the phase 1/2 eNRGy trial and Early Access Program (EAP) of the bispecific antibody Zeno in patients with NRG1+ cancer presented virtually by Lead Author, Dr. Alison Schram of Memorial Sloan Kettering Cancer Center (MSKCC) at the 2022 ASCO Annual meeting.

Merus Presents Clinical Data on Zenocutuzumab (Zeno) in NRG1-fusion (NRG1+) Cancer at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting (Oral Abstract)

The mean of analysts' price targets for Merus N.V. (MRUS) points to an 113.4% upside in the stock.

Does Merus N.V. (MRUS) Have the Potential to Rally 113% as Wall Street Analysts Expect?

UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 03, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the Jefferies Healthcare Conference on Friday, June 10 at 12:45 p.m. ET.

Merus to Participate in a Fireside Chat at the Jefferies Healthcare Conference

- Robust 34% overall response rate and 9.1 months median duration of response across multiple NRG1+ tumor types

Merus Announces Publication of Abstract of Zenocutuzumab in NRG1-fusion (NRG1+) Cancer at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Merus N.V. (MRUS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Down 32.1% in 4 Weeks, Here's Why Merus N.V. (MRUS) Looks Ripe for a Turnaround

The heavy selling pressure might have exhausted for Merus N.V. (MRUS) as it is technically in oversold territory now.

Merus N.V. (MRUS) Loses 30.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will present at the H.C. Wainwright Global Investment Conference.

Merus to Present at the H.C. Wainwright Global Investment Conference

- Zenocutuzumab clinical abstract selected for oral presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting - Company to host investor call on Sunday, June 5 at 6:00 p.m. CT - Clinical data update of petosemtamab (Peto) and MCLA-129 planned for second half of 2022

Merus Announces Financial Results for the First Quarter 2022 and Provides Business Update

UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the selection of an abstract for oral presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Chicago, Illinois on June 3-7, 2022.

Zenocutuzumab Clinical Abstract Selected for Oral Presentation at the 2022 American Society of Clinical Oncology Annual Meeting

UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 25, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced publication of a preclinical report on petosemtamab (Peto, MCLA-158: LGR5 x EGFR Biclonics®) in the journal Nature Cancer . The publication will be available at 11:00 a.m. ET today. The report describes the use of the company's Biclonics® platform to perform a large-scale functional screen of bispecific antibodies resulting in selection of Peto, a bispecific antibody targeting the epidermal growth factor receptor (EGFR) and the leucine-rich repeat containing G protein-coupled receptor (LGR5). Peto displayed potent growth inhibition of colorectal cancer (CRC) organoids, blockade of metastasis initiation and tumor outgrowth in preclinical models of different tumor types. Peto specifically triggered EGFR degradation in organoids expressing LGR5, while showing minimal toxicity towards normal LGR5-expressing organoids.

Merus Announces Publication in Nature Cancer on Petosemtamab's (MCLA-158) Unique Mechanism of Action

BioCryst Pharmaceuticals

BioNTech SE

Exelixis

iTeos Therapeutics, Inc.

Moderna

Pfizer

In these tumultous economic times, look to sectors that are outside the turmoil. Each of these seven biotech stocks fit the bill.

7 Top-Rated Biotech Stocks to Buy for Q2

– MCLA-129 promotes Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and Antibody-Dependent Cell-Mediated Phagocytosis (ADCP) of non-small cell lung cancer (NSCLC) cells– MCLA-129 significantly inhibits growth of a patient-derived EGFR exon20 insertion (exon20ins) tumor in a preclinical xenograft model

Merus Presents Preclinical Data on MCLA-129 at the American Association for Cancer Research Annual Meeting 2022

UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 06, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the 21st Annual Needham Virtual Healthcare Conference on Wednesday, April 13 at 10:15-10:55 a.m. ET.

Merus to Participate in a Fireside Chat at the 21st Annual Needham Virtual Healthcare Conference

- The poster details the mechanism of action of MCLA-129 in vitro and effectiveness in vivo in an EGFR exon20 insertion (ex20ins) non-small cell lung cancer (NSCLC) model - The poster details the mechanism of action of MCLA-129 in vitro and effectiveness in vivo in an EGFR exon20 insertion (ex20ins) non-small cell lung cancer (NSCLC) model

Merus Announces Publication of Abstract on MCLA-129 at the American Association for Cancer Research 2022 Annual Meeting

As of February 2022, more than 100 patients with NRG1 gene fusion positive (“NRG1+”) cancer have been treated with zenocutuzumab (“Zeno”) monotherapy

Merus Announces Financial Results for the Fourth Quarter and Full Year 2021 and Provides Business Update

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 25, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the appointment of Shannon Campbell as Executive Vice President & Chief Commercial Officer. Ms. Campbell is an accomplished healthcare leader with demonstrated success leading commercial businesses across a range of specialty markets, including oncology.

Merus Appoints Shannon Campbell as Chief Commercial Officer and Regains Worldwide Rights to MCLA-145

- The primary endpoint of Clinical Benefit Rate at 24 weeks with the triplet combination was met

Merus Presents Updated Analysis of Zenocutuzumab, Trastuzumab, and Vinorelbine in Patients with HER2+ Metastatic Breast Cancer at the San Antonio Breast Cancer Symposium

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today released clinical data on MCLA-145 from the phase 1 trial in patients with solid tumors at the ESMO Immuno-Oncology Congress 2021 being held virtually.

Merus Presents Clinical Data on MCLA-145 at the ESMO Immuno-Oncology Congress 2021

Merus N.V. (MRUS) delivered earnings and revenue surprises of 40.91% and 29.84%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Merus N.V. (MRUS) Reports Q3 Loss, Tops Revenue Estimates

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 02, 2021 (GLOBE NEWSWIRE) --  Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced a regulatory update for the zenocutuzumab (Zeno) program in NRG1 positive (NRG1+) solid tumors, financial results for the third quarter that ended September 30, 2021, and provided a business update.

Merus Announces Regulatory Update on Zenocutuzumab, Financial Results for the Third Quarter and Provides Business Update

Merus N.V. (MRUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Merus N.V. (MRUS) Report Negative Q3 Earnings?

Merus N.V. (MRUS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Strength Seen in Merus N.V. (MRUS): Can Its 37.5% Jump Turn into More Strength?

The stock price Merus NV (NASDAQ: MRUS) increased by over 35% today. This is why it happened.

MRUS Stock: Why It Substantially Increased Today

This biotech's second experimental cancer drug to begin clinical trials produced some encouraging results.

News for Merus Stock (MRUS)